Photocure (DB:PHS) - Hisse Senedi Fiyatı, Haberler ve Analizler

PHS Stoklara Genel Bakış

PHS temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	3/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 87.2% daha düşük bir oranda işlem görüyor

Kazançların yılda 94.94% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Risk Analizi

Hisse senetleri oldukça likit değildir

Photocure ASA Rakipler

Pierrel

DB:2FJ0

€92.8m

PharmaSGP Holding

XTRA:PSG

€287.8m

MPH Health Care

DB:93M1

€105.3m

Dermapharm Holding

XTRA:DMP

€2.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Photocure
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	NOK 4.41
52 Haftanın En Yüksek Seviyesi	NOK 4.84
52 Haftanın En Düşük Seviyesi	NOK 4.28
Beta	0.99
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-62.72%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-25.88%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	PHS	DE Pharmaceuticals	DE Pazar
7D	0%	1.4%	0.8%
1Y	n/a	-18.4%	9.1%

Getiri vs. Endüstri: PHS un German Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: PHS un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is PHS's price volatile compared to industry and market?
PHS volatility
PHS Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: PHS hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: PHS 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1993	102	Dan Schneider	www.photocure.com

Photocure ASA, bağlı ortaklıkları ile birlikte İskandinav ülkeleri, Almanya, Fransa, Avusturya, Birleşik Krallık, BeNeLux, İtalya, diğer Avrupa Ülkeleri, Kanada ve Amerika Birleşik Devletleri'nde farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi, dağıtımı, pazarlanması ve satışı ile ilgilenmektedir. Ticari Franchise ve Geliştirme Portföyü segmentleri aracılığıyla faaliyet göstermektedir. Şirket, mesane kanserinin tespiti ve yönetimi için Hexvix/Cysview'i sunmaktadır.

Photocure ASA Temel Bilgiler Özeti

Photocure'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PHS temel i̇stati̇sti̇kler
Piyasa değeri	€117.53m
Kazançlar(TTM)	€1.22m
Gelir(TTM)	€45.18m

96.6x

F/K Oranı

2.6x

P/S Oranı

PHS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PHS gelir tablosu (TTM)
Gelir	NOK 526.25m
Gelir Maliyeti	NOK 29.11m
Brüt Kâr	NOK 497.15m
Diğer Giderler	NOK 482.98m
Kazançlar	NOK 14.16m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.52
Brüt Marj	94.47%
Net Kâr Marjı	2.69%
Borç/Özkaynak Oranı	0%

PHS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PHS Stoklara Genel Bakış

Ödüller

Risk Analizi

Photocure ASA Rakipler

DB:2FJ0

€92.8m

XTRA:PSG

€287.8m

DB:93M1

€105.3m

XTRA:DMP

€2.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Recent updates

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Less than half of directors are independent

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.81 loss in 1Q 2022)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

New 90-day high: €10.40

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

New 90-day high: €9.02

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Photocure ASA Temel Bilgiler Özeti

96.6x

2.6x

Kazanç ve Gelir